TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04372628

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir 400 mg/100 mg
Description: Lopinavir/Ritonavir tablets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Unmatched placebo
Study: NCT01903421

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia group: bupivacaine 10-15mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia group: induction propofol 1.5-2mg/kg and fentanyl 1-3g/kg, maintained with isoflurane or sevoflurane

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Blood test
Description: DNA will be tested for the presence of ε4 allele of the apolipoprotein E gene

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Blood test
Description: DNA will be tested for the presence of ε4 allele of the apolipoprotein E gene

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar spinal tap
Description: 1ml of cerebrospinal fluid (CSF) removed and stored for further analysis of amyloid tau protein after completion of the study
Study: NCT00206687

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spheramine (BAY86-5280)
Description: Bilateral implantation of Spheramine into the postcommissural putamen, each side at a dose of 325,000 cells
Study: NCT01903421

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar spinal tap
Description: 1ml of cerebrospinal fluid (CSF) removed and stored for further analysis of amyloid tau protein after completion of the study

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Montreal Cognitive Assessment (MOCA) and MMSE

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Montreal Cognitive Assessment (MOCA) and MMSE
Study: NCT01037439

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adaptive Servo-controlled Ventilation (ASV)
Description: Pressure support ventilation adapts to meet a target ventilation level that is constantly being assessed

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive Servo-controlled Ventilation (ASV)
Description: Pressure support ventilation adapts to meet a target ventilation level that is constantly being assessed
Study: NCT04416893

Intervention type: DIAGNOSTIC_TEST
Intervention: RT-PCR SARS-Cov2
Description: nasopharyngeal swab will be taken for detection of SARS-CoV-2 by RT-PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Sars-Cov2 serology
Description: A microsample of blood will be taken for serology
Study: NCT02288754

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: No intervention except to collect blood for diagnostic test development

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: No intervention except to collect blood for diagnostic test development

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: No intervention except to collect blood for diagnostic test development
Study: NCT02062359

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells
Description: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-NY ESO-1 T cell receptor (TCR) CD62L+ cells and high dose aldesleukin.~On day 0, cells (1x10e9 to 2x10e11) will be infused intravenously on the Patient Care Unit over 20-30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: On days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: On days -5 to -1: Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
Study: NCT03128424

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PQ Bypass Stent Graft System
Description: The PQ Bypass™ Stent Graft System is indicated to improve luminal diameter in the treatment of patients with symptomatic de novo or restenotic native lesions or occlusions of the superficial femoral artery (SFA) and/or proximal popliteal artery, with reference vessel diameters of 5.0 to 6.7 mm and lesion lengths up to 180 mm.
Study: NCT00214305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Range of Motion Therapy Program
Description: The program involves exercises and maneuvers that include voluntary maximal movements of the tongue, pitch range exercises, head lifting (Shaker exercise), resistance to laryngeal excursion (Mendelsohn Maneuver), breath holding after swallow and cough, thermal-tactile stimulation (ice), suck-swallow, optimal posturing, and dietary changes.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Postural Sensory Therapy Program
Description: The program involves all of the above, except that range of motion exercises (voluntary maximal movements of the tongue, pitch range exercises, head lifting, resistance to laryngeal excursion, breath holding after swallow and cough) are not performed.
Study: NCT04279314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trofinetide
Description: Trofinetide solution of 30-60 mL based on subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
Study: NCT03026218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GlucoseMama application with blood sugar monitoring and carb monitoring.
Description: We will use the Glucosemama application to review glucose and carb logs on a weekly basis. This will be reviewed with the patient in order to adjust dietary and medicals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GlucoseMama application with blood sugar monitoring and carb monitoring.
Description: We will use the Glucosemama application to review glucose and carb logs on a weekly basis. This will be reviewed with the patient in order to adjust dietary and medicals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group prenatal care for GDM.
Description: group prenatal care is a group based intervention where individuals with GDM will meet together to learn about pregnancy and diabetes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group prenatal care for GDM.
Description: group prenatal care is a group based intervention where individuals with GDM will meet together to learn about pregnancy and diabetes.
Study: NCT04189354

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (t-DCS) device
Description: t-DCS is a brain electrostimulation technique that consists of applying a current of low intensity (between 1 and 2 mA) on the scalp via two electrodes, in order to modify the cerebral activity of the stimulated zones. The investigators use the Soterix Medical t-DCS devices of the mini-CT 1x1 type.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (t-DCS) device
Description: t-DCS is a brain electrostimulation technique that consists of applying a current of low intensity (between 1 and 2 mA) on the scalp via two electrodes, in order to modify the cerebral activity of the stimulated zones. The investigators use the Soterix Medical t-DCS devices of the mini-CT 1x1 type.
Study: NCT02546934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX, cisplatin
Description: ABX 125 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine, Cisplatin
Description: Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
Study: NCT03611153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4831 Oral Myeloperoxidase Inhibitor
Description: A single administration dose of 30 mg oral MPO inhibitor given orally following baseline, resting and exercise testing in patients during right heart catheterization.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: A single administration dose of 30 mg placebo given orally following baseline, resting and exercise testing in patients during right heart catheterization.
Study: NCT03284034

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CoolCurve
Description: The right and left sides of the upper back fat will be randomly assigned to receive Cryolypolysis (CoolCurve + Advantage applicator) 35 minutes session, 3 sessions 30 days apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101
Description: The right and left sides of the upper back fat will be randomly assigned to receive The right and left sides of the upper back fat will be randomly assigned to receive ATX-101 (deoxycholic acid) injections, 3 sessions, 30 days apart.
Study: NCT03664505

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression garment (manual)
Description: Garment based on manual measurement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression garment (scan)
Description: Garment based on scan measurement
Study: NCT01964326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin calcium 10 mg
Description: Atorvastatin calcium 10 mg tablet to be administered orally every day
Study: NCT00790452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 325 mg daily by mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet daily by mouth
Study: NCT01239667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual oriented planning of the rehabilitation program for patients with heart failure
Description: Individual oriented rehabilitation plan in collaboration with the patient followed by measuring health related quality of life and self care behavior
Study: NCT04188379

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efgartigimod
Description: Intravenous infusion of efgartigimod

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of placebo
Study: NCT01089322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled corticosteroid plus LABA plus oral corticosteroid
Description: formoterol plus budesonide 12/400mcg 2times/day and 6/200 mcg as needed and prednisone 40 mcg
Study: NCT03166150

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-modal rehabilitation program
Description: Patients will receive 12 weeks of exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Physical therapy
Description: Pelvic Floor Physical therapy
Study: NCT02582346

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI acquisition - no contrast agent
Description: No surgery. Volunteers will have an MRI with a 3T clinical system. Installation will be performed according to standard protocols. Different neurography and tractography sequences will be acquired in order to get different contrasts.
Study: NCT04082884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Very Low Carbohydrate Diet
Description: A very low carbohydrate diet (VLCD), is defined as limiting carbohydrate intake to 11% of total daily caloric intake.
Study: NCT00206687

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Sham surgery procedure without penetration of the dura mater. Nothing wil be implanted into the brain.
Study: NCT04131270

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planning + Education
Description: Planning: Participants will fill in the planning forms that efer to replacing sedentary behavior with physical activity.~The following behavior change techniques are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all behavior change techniques would include references to planning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: The education would include extended sedentary behavior and physical activity education, delivered face-to-face by the experimenters. The education includes: (1) the behavioral guidelines, tailored to age and health status of the participants, (2) the examples of exercises and their metabolic equivalent, and (3) the education about ways to break sedentary behavior with active breaks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: The education would include extended sedentary behavior and physical activity education, delivered face-to-face by the experimenters. The education includes: (1) the behavioral guidelines, tailored to age and health status of the participants, (2) the examples of exercises and their metabolic equivalent, and (3) the education about ways to break sedentary behavior with active breaks.
Study: NCT02427659

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Virtual Reality Distraction
Description: The subjects will receive a 20-minute Virtual Reality Distraction (VRD) during their wound care procedure. The nurse will be doing their wound care.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Audio (sound of nature)
Description: The subjects will listen to an audio recording called Sounds of Nature during their wound care.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control standard nurse wound care
Description: The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
Study: NCT01007656

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GD Antrodia camphorata
Description: Three 500mg capsules per oral dose, twice daily with an interval of 12 hours for 90 days
Study: NCT00337272

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken 30 minutes before bedtime days 1-28 of treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramelteon
Description: 8 mgs daily for days 1-28 of treatment period
Study: NCT05008952

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-fat shake
Description: All participants will be given a high-fat test meal to examine their postprandial triglyceride response.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-fat shake
Description: All participants will be given a high-fat test meal to examine their postprandial triglyceride response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat shake
Description: All participants will be given a high-fat test meal to examine their postprandial triglyceride response.
Study: NCT00659490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1940
Description: 800ug oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: 500mg oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given pre-surgery
Study: NCT02341508

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg Lpathomab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg Lpathomab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3.0 mg/kg Lpathomab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 mg/kg Lpathomab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20 mg/kg Lpathomab

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution for intravenous infusion
Study: NCT01375270

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glucotoxicity
Description: Glucose will be infused intravenously for a 24 hour period to raise blood glucose concentrations 5 mM above basal.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipotoxicity
Description: Intralipid and heparin will be infused intravenously for a 24 hour period to raise blood free fatty acid concentrations to approximately 1 mM.
Study: NCT00827541

Intervention type: DRUG
Intervention: Tigecycline
Description: Tigecycline 50 or 100 mg intravenously. Therapy conducted according to the package leaflet of Tygacil and to international treatment guidelines. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.
Study: NCT02115867

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Description: Symprove probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Symprove probiotic
Study: NCT01959425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Off OAT Group (Test)
Description: Discontinuation of OAT Therapy

Intervention type: OTHER
Group type: OTHER
Intervention: On OAT Group (Control)
Description: Continuation of OAT Therapy
Study: NCT05078151

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Whole-Body Diffusion Weighted MRI
Description: MRI at baseline, after four and eight weeks of treatment and at disease progression or treatment discontinuation.
Study: NCT03017417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Various exercise tests

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: standard treatment
Study: NCT02437656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: J3 - J10 (7 days minimum) : 850 mg 2 times / day~J10 - 48h before surgery : 850 mg 3 times / day
Study: NCT02623465

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Administered subcutaneously (SC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered subcutaneously (SC)
Study: NCT02192905

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program Lifestyle Intervention
Study: NCT03870997

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Digital Intervention
Description: The Diabetes Digital Intervention is a digital campaign that provides interactive ways (e.g., videos, infographics, quizzes) for individuals to learn about influenza and related complications, and the importance of influenza vaccination. It is tailored to people living with diabetes and highlights the importance of influenza vaccination for this specific patient population.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Generic Digital Intervention
Description: The Generic Digital Intervention is a digital campaign that provides interactive ways (e.g., videos, infographics, quizzes) for individuals to learn about influenza and related complications, and the importance of influenza vaccination. It provides generic influenza vaccination interventions that can be applicable to any adult who should receive influenza vaccination.
Study: NCT02046291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Romiplostim at the assigned dose will be administered subcutaneously (SQ) once a week for 6 weeks. The dose will be assigned at the time of subject registration. This is a dose escalation to determine the maximum tolerated dose. The doses include 4 mcg/kg/dose, 6 mcg/kg/dose, 8 mcg/kg/dose, and 10 mcg/kg/dose.
Study: NCT02729155

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPre
Description: Preconditioning 200 mmHg x 5 minutes before procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPre
Description: Preconditioning 200 mmHg x 5 minutes before procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPost
Description: Postconditioning 200 mmHg x 5 minutes after procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPost
Description: Postconditioning 200 mmHg x 5 minutes after procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham-Pre
Description: Sham 10 mmHg x 5 minutes before procedure

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham-Pre
Description: Sham 10 mmHg x 5 minutes before procedure
Study: NCT04421222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-7386 (QD)
Description: Once daily oral dose of EPI-7386
Study: NCT02729155

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham-Post
Description: Sham 10 mmHg x 5 minutes after procedure

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham-Post
Description: Sham 10 mmHg x 5 minutes after procedure
Study: NCT02623465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Administered subcutaneously (SC)
Study: NCT01888211

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acid supplementation
Description: 2 grams Omacor daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive Oil
Description: 2 grams olive oil daily
Study: NCT01683760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Prophylactic fluconazole administration in VLBW infants
Study: NCT04626739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T
Description: CD19 CAR-T for CD19 positive R/R non-Hodgkin lymphoma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD22 CAR-T
Description: CD22 CAR-T for CD22 positive R/R non-Hodgkin lymphoma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19+CD22 CAR-T
Description: CD19+CD22 CAR-T for CD19 positive and CD22 positive R/R non-Hodgkin lymphoma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25mg/㎡ for D-4、D-3 and D-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500mg/㎡ for D-3 and D-2
Study: NCT01718028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Propylene glycol 0.6% ocular emulsion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium chloride 0.9% saline solution
Study: NCT02650219

Intervention type: GENETIC
Intervention: genetic analyses

Intervention type: GENETIC
Intervention: genetic analyses
Study: NCT02167763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VeraCept Intrauterine Copper Contraceptive

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TCu380 IUD